Attached files
| file | filename |
|---|---|
| EX-99.1 - ALBANY MOLECULAR RESEARCH INC | v207843_ex99-1.htm |
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 13, 2011
ALBANY
MOLECULAR RESEARCH, INC.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-25323
|
14-1742717
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
21
Corporate Circle, P.O. Box 15098, Albany, NY
|
12212
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (518) 512-2000
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions ( see
General Instruction A.2. below) :
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01 Regulation FD Disclosure
We are
furnishing this Current Report on Form 8-K in connection with the disclosure of
information, in the form of an excerpt of textual information from a powerpoint
presentation to be given at meetings with institutional investors. This
information may be amended or updated at any time and from time to time through
another Form 8-K, a later company filing, or other means.
The
information in this Current Report on Form 8-K (including the exhibit) is
furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for
the purpose of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that section. This Current Report on
Form 8-K will not be deemed an admission as to the materiality of any
information in the Report that is required to be disclosed solely by
Regulation FD.
We do not
have, and expressly disclaim, any obligation to release publicly any updates or
any changes in our expectations or any change in events, conditions, or
circumstances on which any forward-looking statement is based.
The text
included with this Report on Form 8-K is available on our website located at
www.amriglobal.com, although we reserve the right to discontinue that
availability at any time.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
|
Exhibit
|
||
|
Number
|
Exhibits
|
|
|
99.1
|
AMRI
presentation dated January 13,
2011.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Date:
January 13, 2011
|
ALBANY
MOLECULAR RESEARCH, INC.
|
|
|
By:
|
/s/
Mark T. Frost
|
|
|
Name:
Mark T. Frost
|
||
|
Title:
Senior Vice President, Administration,
|
||
|
Chief
Financial Officer and
Treasurer
|
||
EXHIBIT INDEX